marco bregni

Dr. marco bregni

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2009 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
FCFederica Cattaneo
Federica Cattaneo
SGStefania Galimberti
Stefania Galimberti
UBUlrike Benninghoff
Ulrike Benninghoff
BCBarbara Cassani
Barbara Cassani
MRMaria-Grazia Roncarolo
Maria-Grazia Roncarolo
We investigated the long-term outcome of gene therapy for severe combined immunodeficiency (SCID) due to the lack of adenosine deaminase (ADA), a fatal disorder of purine metabolism and immunodeficiency.

1 May 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
FCFabio Ciceri
Fabio Ciceri
CBChiara Bonini
Chiara Bonini
MSMaria Teresa Lupo Stanghellini
Maria Teresa Lupo Stanghellini
ABAttilio Bondanza
Attilio Bondanza
CTCatia Traversari
Catia Traversari
CBClaudio Bordignon
Claudio Bordignon

27 December 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EVEduardo Villablanca
Eduardo Villablanca
LRLaura Raccosta
Laura Raccosta
DZDan Zhou
Dan Zhou
RFRaffaella Fontana
Raffaella Fontana
DMDaniela Maggioni
Daniela Maggioni
VRVincenzo Russo
Vincenzo Russo

1 June 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
PCPaolo Corradini
Paolo Corradini
ADAnna Dodero
Anna Dodero
FZFrancesco Zallio
Francesco Zallio
DCDaniele Caracciolo
Daniele Caracciolo
MCMarco Casini
Marco Casini
CTCorrado Tarella
Corrado Tarella
Purpose Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of malignancies characterized by a poor prognosis. We performed a pilot study to investigate the role of reduced-intensity conditioning (RIC) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs. Patients and Methods We have conducted a phase II trial on 17 patients receiving salvage chemotherapy followed by RIC and allogeneic transplantation of hematopoietic cells. The RIC regimen consisted of thiotepa, fludarabine, and cyclophosphamide. The acute graft-versus-host disease prophylaxis consisted of cyslosporine and short course methotrexate. Results Patients had a median age of 41 years (range, 23 to 60 years). Two patients were primary chemorefractory, and 15 had relapsed disease; eight patients (47%) had a disease relapse after an autologous transplantation. After a median follow-up of 28 months from the day of study entry (range, 3 to 57 months), 14 of 17 patients were alive (12 in complete remission, one in partial remission, and one with stable disease), two died as a result of progressive disease, and one died as a result of sepsis concomitant to acute graft-versus-host disease. The estimated 3-year overall and progression-free survival rates were 81% (95% CI, 62% to 100%) and 64% (95% CI, 39% to 89%), respectively. The estimated probability of nonrelapse mortality at 2 years was 6% (95% CI, 1% to 17%). Donor lymphocyte infusions induced a response in two patients progressing after allografting. Conclusion RIC followed by allogeneic stem-cell transplantation is feasible, has a low treatment-related mortality, and seems to be a promising salvage treatment for relapsed PTCL. These findings suggest that the existence of a graft-versus-T-cell lymphoma effect.

1 June 2002 in Blood
Verified
Journal Article
Closed access
PDF file
MBmarco bregni
marco bregni
ADAnna Dodero
Anna Dodero
JPJacopo Peccatori
Jacopo Peccatori
APAlessandra Pescarollo
Alessandra Pescarollo
MBMassimo Bernardi
Massimo Bernardi
PCPaolo Corradini
Paolo Corradini
The feasibility and toxicity of allogeneic stem cell transplantation after nonmyeloablative conditioning including thiotepa, fludarabine, and cyclophosphamide have been investigated in 6 patients with breast cancer and 7 patients with renal cell cancer. The program included the use of escalating doses of donor lymphocyte infusions (DLI) and/or interferon alpha (IFNα) for patients showing no tumor response and no graft-versus-host disease (GVHD). Patients were at high risk of transplant-related mortality (TRM) because of age, advanced stage, and previous treatments. We observed a partial remission in 4 renal cancer and in 2 breast cancer patients (one at the molecular level in the bone marrow), occurring after cyclosporine withdrawal or after DLI and/or IFNα. All the responses were accompanied by the occurrence of acute GVHD. We conclude that reduced-intensity allogeneic stem cell transplantation is a feasible procedure in renal and breast cancer, and that the exploitation of graft-versus-tumor effect after DLI is a promising finding.

1 June 2005 in Blood
Verified
Journal Article
Open access
PDF file
RCRita Clementi
Rita Clementi
FLFranco Locatelli
Franco Locatelli
LDLoïc Dupré
Loïc Dupré
AGAlberto Garaventa
Alberto Garaventa
LELorenzo Emmi
Lorenzo Emmi
MRMaria Grazia Roncarolo
Maria Grazia Roncarolo
Perforin mutations have been demonstrated in a proportion of patients diagnosed with the familial form of hemophagocytic lymphohistiocytosis (HLH). In the present study, we evaluated whether some patients with lymphoma sharing clinical characteristics with HLH might harbor mutations of the perforin gene. We analyzed 29 patients and found that 4 patients, who developed either Hodgkin or non-Hodgkin lymphoma, had biallelic mutations of the perforin gene. One of these 4 patients, a 19-year-old female with T-cell lymphoma, had a brother carrying the same mutations who developed HLH. In 2 of the 4 patients with biallelic mutations of the perforin gene, we evaluated perforin expression by flow cytometry and natural killer (NK) activity and both were found to be absent. Moreover, we documented the presence of monoallelic mutations of the perforin gene in 4 more patients. One of these 4 latter patients also carried a mutation of the Fas gene. These data indicate that perforin deficiency, either alone or in combination with other mutations of genes involved in lymphocyte survival or functional activity, may be present in patients with lymphoma. These findings suggest that perforin also plays a key role in the mechanisms of immune surveillance that prevent tumor growth and/or development.